Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | USP14 | P54578 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21688035 | 0.97 | NR3C1 (0.33) | NR3C1TDP2ALDH1A1LMNAHPGD | |
| SCHEMBL21688033 | 0.92 | TDP2 (0.35) | TDP2ALDH1A1G6PDUSP14CYP19A1 | |
| SCHEMBL21687992 | 0.90 | TDP2 (0.34) | TDP2G6PDUSP14CYP19A1 | |
| SCHEMBL21687990 | 0.90 | ALDH1A1 (0.34) | NR3C1TDP2ALDH1A1LMNAHPGD | |
| SCHEMBL21687469 | 0.90 | GABRA1 (0.36) | NR3C1TDP2ALDH1A1LMNAHPGD | |
| SCHEMBL21688216 | 0.89 | KDM4E (0.37) | TDP2G6PDUSP14CYP19A1KDM1A | |
| SCHEMBL21687835 | 0.88 | RARG (0.33) | TDP2ALDH1A1LMNAMAPK1G6PD | |
| SCHEMBL21687986 | 0.88 | KDM4E (0.40) | NR3C1ALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL21687748 | 0.87 | PTGER4 (0.36) | TDP2USP14 | |
| SCHEMBL21687467 | 0.87 | SMN1; SMN2 (0.32) | NR3C1TDP2SMN1; SMN2ESR2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-12-14 | — | — | US | disclosed |
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | CRY1, CCNL2, CCNE2 | NR3C1 667/4885TDP2 4123/4885ALDH1A1 616/4885 |
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | CRY1, CCNL2, CCNE2 | NR3C1 667/4885TDP2 4123/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.